-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Cefalexin Capsules Have Passed Evaluation, and Its Doxazosin Mesylate API Was Approved on the Same Day
Category:
发布时间：2024-04-08
【概要描述】
Spring tides are surging, and good news is coming one after another. On April 8, the cefalexin capsules (0.25 g and 0.125 g) submitted by Shijiazhuang Sihua Pharmaceutical Group were approved by the National Medical Products Administration, having passed the evaluation of quality and therapeutic equivalence for generic drugs. In addition, doxazosin mesylate, submitted by the Group’s Hebei Guolong Pharmaceutical Co., Ltd., was also approved on the same day and registered as an active pharmaceutical ingredient for use in marketed dosage forms.
Spring tides are surging, and good news keeps pouring in. On April 8, the cefalexin capsules (0.25 g and 0.125 g) submitted by Shijiazhuang Sihua Pharmaceutical Group were approved by the National Medical Products Administration, having passed the evaluation of quality and therapeutic equivalence for generic drugs. In addition, doxazosin mesylate, submitted by the Group’s Hebei Guolong Pharmaceutical Co., Ltd., was also approved on the same day and registered as an active pharmaceutical ingredient for use in marketed dosage forms.
According to available information, cefalexin capsules are primarily indicated for the treatment of respiratory tract infections caused by susceptible bacteria, including acute tonsillitis, pharyngitis, sinusitis, bronchitis, and pneumonia, as well as otitis media, urinary tract infections, and skin and soft-tissue infections. Doxazosin mesylate, as an antihypertensive agent, is mainly used in patients with primary mild to moderate hypertension and in hypertensive patients with benign prostatic hyperplasia.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has been driven by innovation and aligned with national development strategies and market demands, striving to build an integrated “active pharmaceutical ingredient plus finished dosage form” development advantage. The company has steadily accumulated research and innovation achievements, with the number of applications submitted and approvals obtained repeatedly reaching new highs. To date, a total of 79 drug varieties comprising 108 specifications have either passed or are deemed to have passed the bioequivalence evaluation for generic drugs.
The head of the group’s R&D center stated that the next step will be to fully leverage the enterprise’s pivotal role in scientific and technological innovation, continuously advance high-level self-reliance and strength in science and technology, focus on the cutting edge of industrial development, constantly optimize the structure and layout of the innovation chain, enhance original innovation capabilities, and develop and produce more “Chinese medicines” tailored to the genetic heritage and physical characteristics of the Chinese population, thereby better serving the health needs of the people.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091